Related Experiment Video
Updated: Aug 17, 2026

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)
Published on: September 11, 2012
Polyamines reverse non-steroidal anti-inflammatory drug-induced toxicity in human colorectal cancer cells
Alun Hughes1, Nicholas I Smith, Heather M Wallace
1Department of Medicine, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK.
Abstract:
Naproxen, sulindac and salicylate, three NSAIDs (non-steroidal anti-inflammatory drugs), were cytotoxic to human colorectal cancer cells in culture. Toxicity was accompanied by significant depletion of intracellular polyamine content. Inhibition of ornithine decarboxylase (the first enzyme of the polyamine biosynthetic pathway), induction of polyamine oxidase and spermidine/spermine N(1)-acetyltransferase (the enzymes responsible for polyamine catabolism) and induction of polyamine export all contributed to the decreased intracellular polyamine content. Morphological examination of the cells showed typical signs of apoptosis, and this was confirmed by DNA fragmentation and measurement of caspase-3-like activity. Re-addition of spermidine to the cells partially prevented apoptosis and recovered the cell number. Thus polyamines appear to be an integral part of the signalling pathway mediating NSAID toxicity in human colorectal cancer cells, and may therefore also be important in cancer chemoprevention in humans.
Insights
Non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen induce colorectal cancer cell death by depleting polyamines. Restoring polyamine levels partially prevents this NSAID-induced apoptosis, suggesting a role in cancer chemoprevention.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
- Colorectal cancer (CRC) remains a significant global health challenge.
- The molecular mechanisms underlying NSAID effects on cancer cells are not fully understood.
Purpose of the Study:
- To investigate the role of intracellular polyamines in NSAID-induced cytotoxicity in human colorectal cancer cells.
- To elucidate the specific polyamine metabolic pathways involved in NSAID toxicity.
- To explore the potential of polyamines in cancer chemoprevention strategies.
Main Methods:
- Human colorectal cancer cells were treated with NSAIDs (naproxen, sulindac, salicylate).
- Intracellular polyamine levels, polyamine metabolic enzyme activities (ornithine decarboxylase, polyamine oxidase, spermidine/spermine N(1)-acetyltransferase), and polyamine export were measured.
- Apoptosis was assessed via morphological changes, DNA fragmentation, and caspase-3-like activity.
- The effect of exogenous spermidine re-addition on NSAID-induced apoptosis was evaluated.
Main Results:
- NSAIDs exhibited significant cytotoxicity towards human colorectal cancer cells in vitro.
- Cytotoxicity correlated with a marked decrease in intracellular polyamine content.
- NSAIDs modulated polyamine metabolism by inhibiting synthesis and inducing catabolism and export.
- NSAID treatment induced apoptosis, confirmed by DNA fragmentation and caspase-3-like activity.
- Supplementation with spermidine partially rescued cells from apoptosis and restored cell numbers.
Conclusions:
- Polyamines are integral to the signaling pathway mediating NSAID toxicity in human colorectal cancer cells.
- NSAID-induced apoptosis in CRC cells is significantly influenced by alterations in polyamine homeostasis.
- Targeting polyamine metabolism could represent a novel strategy for colorectal cancer chemoprevention.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
06:24Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
Published on: October 13, 2023
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents